If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-2

BIONi010-C ApoE E3/E3 #H8 P32

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Immediately available for distribution*
*Once all legal and processing details completed
Timepoint: Confluence
Magnification: x4
Timepoint: Confluence
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-2
Alternative name(s)
BIONi010-C ApoE E3/E3 #H8 P32
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
UKBi011-A-3
(ApoE 3/3)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
UKBi011-A-4
(ApoE 3/4)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
UKBi011-A-1
(iLB-AD + ApoE KO)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
STBCi006-A-1
(ApoE KO)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
BIONi037-A-2
(BIONi037-A ApoE2/2 #M10-7)
BIONi037-A-3
(BIONi037-A ApoE3/4 #P10-22)
BIONi037-A-4
(BIONi037-A ApoE4/4 #I10-53)
BIONi037-A-1
(16423 ApoE KO)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C
(BIONi010-C, K3P53)
UKBi011-A-2
(ApoE 2/2)
Donor's gene variants:
APOE, APOE
Donor diseases:
Alzheimer disease
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-18
(BIONi010-C TBK1 KO)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
Notes This line is part of a set of isogenic APOE lines based on the iPS cell line BIONi010-C. The set comprises the following APOE genotypes: • BIONi010-C-6 (APOE 2/2) • BIONi010-C-2 (APOE 3/3) • BIONi010-C (APOE 3/4) • BIONi010-C-4 (APOE 4/4) • BIONi010-C-3 (APOE KO) A DNA SNP array revealed no larger chromosomal aberrations to be reported. An unsignificant duplication of 1,4Mbp was found on Chr22 in q11.23. This duplication was found in all isogenic lines generated from BIONi010-C as well as BIONi010-C. Other isogenic ApoE cell line cohorts are also available, generated from BIONi37-A, UKBi011-A and STBci006-A.

Provider

Depositor Bioneer (BION)
Owner Bioneer (BSC)
Distributors
EBiSC
Derivation country Denmark

External Databases

hPSCreg BIONi010-C-2
BioSamples SAMEA4342705
Cellosaurus CVCL_II81
Wikidata Q54796765

General Information

Publications View all related publications on hPSCreg (9)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium Essential 8
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 18
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 18 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
GATA6
Yes
SOX17
Yes
FOXA2
Yes
PITX1
Yes
GSC
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
NCAM1
Yes
VIM
Yes
DCN
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
NeuroD1
Yes
PAX6
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46 XY
Passage number: 33
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755
This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • AD
  • Alzheimer dementia
  • Alzheimer disease
  • Alzheimer's dementia
  • Alzheimer's disease
  • Alzheimers dementia
  • Alzheimers disease
  • presenile and senile dementia
  • Alzheimer disease, familial
show more synonyms
Genetic modifications
APOE (target)
Isogenic modification
19q13.32
hemizygous
BIONi010-C-2 ApoE3/E3 is an isogenic mutant of BIONi010-C (ApoE3/E4). This APOE3/E3 (BIONi010-C-2) line) line has only a single functional APOE allele due to the presence of on-target unintended insertions caused by CRISPR gene editing in one copy of the alleles. BIONi010-C-2 is hemizygous due to a 3.4 kb insertion from the selection plasmid (used during gene editing) in the coding part of one of the two APOE alleles. The remaining (non-disrupted) allele is correctly transcribed and does drive expression of the expected APOE3/E3 isoform. This is characterised in Schmid B, et al. Corrigendum to "Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line". Stem Cell Res. 2020 Oct; 48:102005. doi: 10.1016/j.scr.2020.102005. Jan;34:101349. PMID: 32971461. The genotype at base position described by rs429358 has been modified in the subclone from T/C to T/T, which changes aa from Arg to Cys; The genotype of base position described by rs7412 in both parent and subclone is C/C, which is an Arg. Together, these base changes define a ApoE3/E3 genotype in the subclone. Please see chromatogram for confirmation of the base changes in the subclone.
Mutated
BIONi010-C-2.jpg
This APOE3/E3 (BIONi010-C-2) line) line has only a single functional APOE allele due to the presence of on-target unintended insertions caused by CRISPR gene editing in one copy of the alleles.
Genetic modifications not related to a disease